Analysts Set Denali Therapeutics Inc. (NASDAQ:DNLI) Price Target at $35.85

Denali Therapeutics Inc. (NASDAQ:DNLI) has been assigned a consensus rating of “Moderate Buy” from the sixteen research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $35.8462.

A number of research analysts recently weighed in on the stock. UBS Group raised their price target on shares of Denali Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Wedbush reaffirmed an “outperform” rating and issued a $26.00 price objective on shares of Denali Therapeutics in a research report on Monday, July 13th. Wall Street Zen lowered shares of Denali Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Friday, July 17th. Finally, Sanford C. Bernstein restated a “hold” rating on shares of Denali Therapeutics in a research note on Monday, June 22nd.

Insider Activity at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 2,768 shares of Denali Therapeutics stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $23.44, for a total transaction of $64,881.92. Following the sale, the insider directly owned 278,995 shares in the company, valued at approximately $6,539,642.80. This trade represents a 0.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of DNLI. Allworth Financial LP increased its position in shares of Denali Therapeutics by 555.0% during the 2nd quarter. Allworth Financial LP now owns 1,834 shares of the company’s stock valued at $47,000 after purchasing an additional 1,554 shares during the last quarter. Nykredit A S purchased a new position in shares of Denali Therapeutics in the 2nd quarter worth about $38,000. Corient Private Wealth LP purchased a new position in shares of Denali Therapeutics in the 2nd quarter worth about $301,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Denali Therapeutics during the second quarter valued at about $368,000. Finally, California State Teachers Retirement System grew its position in Denali Therapeutics by 2,306.0% during the second quarter. California State Teachers Retirement System now owns 3,911,652 shares of the company’s stock valued at $100,608,000 after buying an additional 3,749,076 shares during the period. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Trading Down 0.9%

NASDAQ DNLI opened at $22.08 on Wednesday. The firm has a market capitalization of $3.53 billion, a P/E ratio of -7.77 and a beta of 1.01. The business has a fifty day simple moving average of $24.29 and a 200 day simple moving average of $21.90. Denali Therapeutics has a 12 month low of $12.58 and a 12 month high of $27.30. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The business had revenue of $3.60 million for the quarter, compared to analysts’ expectations of $2.15 million. During the same quarter last year, the company earned ($0.72) earnings per share. On average, analysts predict that Denali Therapeutics will post -2.67 EPS for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.